Importantly, another STAT3 inhibitor, TTI-101, has also been studied in a clinical trial addressing many cancer types, including breast cancer (NCT03195699), suggesting its potential as a therapeutic target [75]. This evidence concerns the gene STAT3 and breast carcinoma.